(Q37612252)

21 August 2017

1 reference

title

Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia (English)

1 reference

21 August 2017

0 references

1 reference

1 reference

Wadworth AN

1

1 reference

PubMed ID

1981869

21 August 2017

Heel RC

series ordinal

2

1 reference

21 August 2017

1 December 1990

1 reference

21 August 2017

1 reference

21 August 2017

40

1 reference

21 August 2017

6

1 reference

21 August 2017

863-879

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199040060-00008

21 August 2017

0 references

cites work

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial

1 reference

12 December 2020

Plasma concentration of remoxipride in relation to antipsychotic effect and adverse symptoms. The Canadian Remoxipride Study Group

1 reference

12 December 2020

Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity

1 reference

12 December 2020

Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride.

1 reference

12 December 2020

An open study of remoxipride, a benzamide derivative, in schizophrenia.

1 reference

12 December 2020

The pathogenesis and management of schizophrenia

1 reference

12 December 2020

Comparison of the effects of the novel antipsychotic agent remoxipride on dopamine and noradrenaline turnover in the rat brain

1 reference

12 December 2020

Down-regulation of central dopamine receptors in schizophrenia

1 reference

12 December 2020

Effects of chronic neuroleptic treatment on agonist affinity states of the dopamine-D2 receptor in the rat brain

1 reference

12 December 2020

Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study

1 reference

12 December 2020

Experiences of long-term treatment with remoxipride: efficacy and tolerability

1 reference

12 December 2020

Biochemistry and behavior: some central actions of amphetamine and antipsychotic drugs

1 reference

12 December 2020

Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain

1 reference

12 December 2020

Drug interaction studies with remoxipride

1 reference

12 December 2020

Clinical pharmacokinetics of remoxipride.

1 reference

12 December 2020

Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models.

1 reference

12 December 2020

Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man.

1 reference

12 December 2020

Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET

1 reference

12 December 2020

Biochemical pharmacology of the atypical neuroleptic remoxipride

1 reference

12 December 2020

Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.

1 reference

12 December 2020

Remoxipride versus thioridazine in elderly psychotic patients

1 reference

12 December 2020

Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity

1 reference

12 December 2020

Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats

1 reference

12 December 2020

Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol

1 reference

12 December 2020

Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia

1 reference

12 December 2020

A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia

1 reference

12 December 2020

A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia

1 reference

12 December 2020

Pharmacokinetics of remoxipride in elderly psychotic patients

1 reference

12 December 2020

Cognitive disturbances in neuroleptic therapy

1 reference

12 December 2020

Fatal intoxication by Remoxipride.

1 reference

12 December 2020

Neuropharmacological and behavioural properties of remoxipride in the rat.

1 reference

12 December 2020

Tolerability and pharmacokinetics of remoxipride after intramuscular administration

1 reference

12 December 2020

Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity

1 reference

12 December 2020

Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration

1 reference

12 December 2020

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol

1 reference

12 December 2020

Remoxipride in schizophrenia. A preliminary report

1 reference

12 December 2020

Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers

1 reference

12 December 2020

An open multicentre study of the treatment of florid schizophrenia with remoxipride.

1 reference

12 December 2020

Effects of remoxipride on psychomotor performance, alone and in combination with ethanol and diazepam.

1 reference

12 December 2020

Plasma concentrations of remoxipride and the gastrointestinal transit of 111In-marked extended-release coated spheres

1 reference

12 December 2020

Pharmacokinetics of remoxipride controlled release and immediate release capsules in schizophrenic patients

1 reference

12 December 2020

Receptor mechanisms in antipsychotic drug action: focus on sigma receptors

1 reference

12 December 2020

A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia.

1 reference

12 December 2020

Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme

1 reference

12 December 2020

Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers

1 reference

12 December 2020

A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia

1 reference

12 December 2020

A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.

1 reference

12 December 2020

A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.

1 reference

12 December 2020

Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.

1 reference

12 December 2020

A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation.

1 reference

12 December 2020

Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia

1 reference

12 December 2020

On stereotypy and catalepsy: studies on the effect of amphetamines and neuroleptics in rats

1 reference

12 December 2020

Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat.

1 reference

12 December 2020

A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia

1 reference

12 December 2020

Dopamine receptors, neuroleptics, and schizophrenia

1 reference

12 December 2020

10.2165/00003495-199040060-00008

Identifiers

DOI

1 reference

PubMed ID

1981869

Dimensions Publication ID

21 August 2017

0 references

1 reference

PubMed ID

1981869